Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Efficacy of Daclizumab in an African-American and Hispanic renal transplant population

  • 3 Accesses

Abstract

Current immunosuppressive regimens have decreased acute rejection rates during the 1st year after renal transplantation. However, this decrease has not been as marked in high-risk groups, such as African-American and Hispanic renal transplant recipients. We compared two simultaneous cohorts of altogether 36 African-American and Hispanic renal transplant recipients. Cohort one received a regimen of mycophenolate mofetil, prednisone, and a calcineurin inhibitor. The second cohort received the same protocol with the addition of Daclizumab (1 mg/kg for five doses given every 2 weeks). The median follow-up was 15.2 months (range 11.8–19.9 months). One patient in the Daclizumab-treated group and seven patients in the control group experienced an acute rejection episode. The rejection-free survival was significantly higher in the Daclizumab-treated group (94.4 %) as compared to the control group (66.7 %, Log-rank < 0.05) at 17 months after transplantation. A Cox Proportional Hazard model revealed lack of Daclizumab therapy as the only significant risk factor for acute rejection. (hazard ratio 7.0, 95 % CI = 1.1–48). The addition of the IL-2 receptor blocker Daclizumab to a triple therapy regimen may decrease early acute rejection in the high-risk groups of African-American and Hispanic patients.

This is a preview of subscription content, log in to check access.

Author information

Additional information

Received: 6 April 1999/Revised: 26 October 1999/Accepted: 23 November 1999

About this article

Cite this article

Meier-Kriesche, H., Palenkar, S., Friedman, G. et al. Efficacy of Daclizumab in an African-American and Hispanic renal transplant population. Transpl Int 13, 142–145 (2000). https://doi.org/10.1007/s001470050675

Download citation

  • Key words Kidney transplantation
  • High-risk population
  • Daclizumab
  • Immunosuppression